IRIS Accounts Production v23.3.0.418 10126344 Board of Directors 1.5.22 31.10.23 31.10.23 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pure101263442022-04-30101263442023-10-31101263442022-05-012023-10-31101263442021-04-30101263442021-05-012022-04-30101263442022-04-3010126344ns16:EnglandWales2022-05-012023-10-3110126344ns15:PoundSterling2022-05-012023-10-3110126344ns11:Director12022-05-012023-10-3110126344ns11:PrivateLimitedCompanyLtd2022-05-012023-10-3110126344ns11:SmallEntities2022-05-012023-10-3110126344ns11:AuditExemptWithAccountantsReport2022-05-012023-10-3110126344ns11:SmallCompaniesRegimeForDirectorsReport2022-05-012023-10-3110126344ns11:SmallCompaniesRegimeForAccounts2022-05-012023-10-3110126344ns11:FullAccounts2022-05-012023-10-3110126344ns11:OrdinaryShareClass12022-05-012023-10-3110126344ns11:Director22022-05-012023-10-3110126344ns11:RegisteredOffice2022-05-012023-10-3110126344ns6:CurrentFinancialInstruments2023-10-3110126344ns6:CurrentFinancialInstruments2022-04-3010126344ns6:ShareCapital2023-10-3110126344ns6:ShareCapital2022-04-3010126344ns6:RetainedEarningsAccumulatedLosses2023-10-3110126344ns6:RetainedEarningsAccumulatedLosses2022-04-3010126344ns6:FurnitureFittings2022-05-012023-10-3110126344ns6:ComputerEquipment2022-05-012023-10-3110126344ns6:FurnitureFittings2022-04-3010126344ns6:ComputerEquipment2022-04-3010126344ns6:FurnitureFittings2023-10-3110126344ns6:ComputerEquipment2023-10-3110126344ns6:FurnitureFittings2022-04-3010126344ns6:ComputerEquipment2022-04-3010126344ns6:WithinOneYearns6:CurrentFinancialInstruments2023-10-3110126344ns6:WithinOneYearns6:CurrentFinancialInstruments2022-04-3010126344ns6:DeferredTaxation2022-04-3010126344ns6:DeferredTaxation2022-05-012023-10-3110126344ns6:DeferredTaxation2023-10-3110126344ns11:OrdinaryShareClass12023-10-31
REGISTERED NUMBER: 10126344 (England and Wales)














UNAUDITED FINANCIAL STATEMENTS

FOR THE PERIOD

1 MAY 2022 TO 31 OCTOBER 2023

FOR

AD BROWN MEDCHEM CONSULTING LIMITED

AD BROWN MEDCHEM CONSULTING LIMITED (REGISTERED NUMBER: 10126344)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE PERIOD 1 MAY 2022 TO 31 OCTOBER 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4

Report of the Accountants 7

AD BROWN MEDCHEM CONSULTING LIMITED

COMPANY INFORMATION
FOR THE PERIOD 1 MAY 2022 TO 31 OCTOBER 2023







DIRECTORS: Dr A D Brown
Miss E Olerenshaw





REGISTERED OFFICE: 45 Queen Street
Deal
Kent
CT14 6EY





REGISTERED NUMBER: 10126344 (England and Wales)





ACCOUNTANTS: Higson & Co (Deal) Ltd
45 Queen Street
Deal
Kent
CT14 6EY

AD BROWN MEDCHEM CONSULTING LIMITED (REGISTERED NUMBER: 10126344)

BALANCE SHEET
31 OCTOBER 2023

2023 2022
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 1,058 1,613

CURRENT ASSETS
Debtors 5 9,363 18,278
Cash at bank 92,751 149,592
102,114 167,870
CREDITORS
Amounts falling due within one year 6 6,154 18,630
NET CURRENT ASSETS 95,960 149,240
TOTAL ASSETS LESS CURRENT
LIABILITIES

97,018

150,853

PROVISIONS FOR LIABILITIES 7 201 306
NET ASSETS 96,817 150,547

CAPITAL AND RESERVES
Called up share capital 8 1,000 1,000
Retained earnings 95,817 149,547
SHAREHOLDERS' FUNDS 96,817 150,547

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 October 2023.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 October 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

AD BROWN MEDCHEM CONSULTING LIMITED (REGISTERED NUMBER: 10126344)

BALANCE SHEET - continued
31 OCTOBER 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 19 February 2024 and were signed on its behalf by:





Dr A D Brown - Director


AD BROWN MEDCHEM CONSULTING LIMITED (REGISTERED NUMBER: 10126344)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD 1 MAY 2022 TO 31 OCTOBER 2023

1. STATUTORY INFORMATION

AD Brown Medchem Consulting Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The registered office address of the business is 45 Queen Street Deal Kent CT14 6EY

The Financial Statements are presented in round pounds sterling £

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates and value added tax

Revenue is recognised when services provided are considered completed.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Fixtures and fittings - 25% on reducing balance
Computer equipment - 33% on cost

Tangible fixed assets are tested for impairment annually.

It is the Company's policy to capitalise items with an estimated useful life in excess of two years.

Taxation
Taxation for the period comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

AD BROWN MEDCHEM CONSULTING LIMITED (REGISTERED NUMBER: 10126344)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE PERIOD 1 MAY 2022 TO 31 OCTOBER 2023

3. EMPLOYEES AND DIRECTORS

The average number of employees during the period was 2 (2022 - 2 ) .

4. TANGIBLE FIXED ASSETS
Fixtures
and Computer
fittings equipment Totals
£    £    £   
COST
At 1 May 2022 1,800 2,568 4,368
Additions - 667 667
At 31 October 2023 1,800 3,235 5,035
DEPRECIATION
At 1 May 2022 1,024 1,731 2,755
Charge for period 267 955 1,222
At 31 October 2023 1,291 2,686 3,977
NET BOOK VALUE
At 31 October 2023 509 549 1,058
At 30 April 2022 776 837 1,613

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade debtors 8,665 17,186
Other debtors 474 473
Directors' current accounts 224 619
9,363 18,278

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade creditors - 120
Tax 5,258 17,730
VAT 6 -
Accrued expenses 890 780
6,154 18,630

7. PROVISIONS FOR LIABILITIES
2023 2022
£    £   
Deferred tax 201 306

AD BROWN MEDCHEM CONSULTING LIMITED (REGISTERED NUMBER: 10126344)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE PERIOD 1 MAY 2022 TO 31 OCTOBER 2023

7. PROVISIONS FOR LIABILITIES - continued

Deferred
tax
£   
Balance at 1 May 2022 306
Provided during period (105 )
Balance at 31 October 2023 201

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2023 2022
value: £    £   
1,000 Ordinary £1 1,000 1,000

9. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

During the year the following loans subsisted;

Directors Current Account
A member of Key Management Personnel

During the year the Director advanced the Company £695 (2022:£5,109)

During the year the Company repaid the Director £300 (2022:£7,725)

As at the year end the Director owes the Company £224 (2022:£619)

The loan is interest free and repayable upon demand. The loan was repaid within 9 months of the year end.

AD BROWN MEDCHEM CONSULTING LIMITED

REPORT OF THE ACCOUNTANTS TO THE DIRECTORS OF
AD BROWN MEDCHEM CONSULTING LIMITED

The following reproduces the text of the report prepared for the directors in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Directors are not required to be filed with the Registrar of Companies.

As described on the Balance Sheet you are responsible for the preparation of the financial statements for the period ended 31 October 2023 set out on pages one to nine and you consider that the company is exempt from an audit.

In accordance with your instructions, we have compiled these unaudited financial statements in order to assist you to fulfil your statutory responsibilities, from the accounting records and information and explanations supplied to us.






Higson & Co (Deal) Ltd
45 Queen Street
Deal
Kent
CT14 6EY


Date: .............................................